Eli Lilly and Company (LLY) Stock Price, Quote, News & Analysis

LLY Eli Lilly and Company
Stock Price & Overview

$802.91-0.26 (-0.03%)4:00 PM 05/22/24
NYSE | $USD | Post-Market: $802.92 +0.01 (+0.00%) 7:59 PM

Charts

52 Week Range
419.80
816.61
Day Range
795.25
804.88
EPS (FWD)
13.76
PE (FWD)
58.36
Div Rate (FWD)
$5.20
Yield (FWD)
0.65%
Market Cap
$723.18B
Volume
1,767,519
Prev. Close
$803.17

Quant Ranking

Ratings Summary

People Also Follow

Similar to LLY

SymbolLast PriceChange
JNJ
0
0.00%
Johnson & Johnson
MRK
0
0.00%
Merck & Co., Inc.
AZN
0
0.00%
AstraZeneca PLC
RHHBY
0
0.00%
Roche Holding AG
PFE
0
0.00%
Pfizer Inc.

LLY Company Profile

Eli Lilly and Company logo
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Employees
43,000
Founded
1876
Address
  • Lilly Corporate Center
  • Indianapolis, IN, 46285
  • United States
Phone Number
317 276 2000

LLY Earnings Per Share

Earnings Estimates

FY
EPS
YoY
PE
Sales
YoY
2024
13.76
+117.74%
58.36
$43.00B
+26.01%
2025
19.00
+38.08%
42.27
$52.61B
+22.36%
2026
24.78
+30.44%
32.41
$62.15B
+18.12%

Earnings Revisions

Rating:
FY1 Up Revisions
23
FY1 Down Revisions
0
0% Down100% Up

Valuation

Rating:
P/E Non-GAAP (FWD)
58.36
P/E GAAP (TTM)
118.28
Price/Book (TTM)
56.44
EV/Sales (TTM)
20.77
EV/EBITDA (TTM)
55.80

Growth

Rating:
Revenue (YoY)
29.76%
Revenue 3 Year (CAGR)
12.13%
EPS Diluted (YoY)
7.97%
EPS Diluted 3 Year (CAGR)
0.55%
Levered FCF (YoY)
-

Profitability

Rating:
Gross Profit Margin
80.16%
EBIT Margin
32.86%
Net Income Margin
17.08%
Return on Equity
50.75%
Return on Assets
9.60%

Momentum

Rating:
Ticker
3M
6M
9M
1Y
LLY
+7.68%
+35.53%
+46.02%
+81.56%
SP500
+6.82%
+17.26%
+20.95%
+26.94%

52 Week Range

419.80
Last price: 802.91
816.61

Capital Structure

Market Cap
$723.18B
Total Debt
$26.35B
Cash
$2.65B
Other
$85.20M
Enterprise Value
$746.26B

Trading Data

Volume
1.77M
Average Volume (3 months)
2.78M
Previous Close
803.17
Open
801.00
Shares Outstanding (Ticker)
900.41M

LLY Dividends

Dividend Yield (FWD)
0.65%
Annual Payout (FWD)
$5.20
Payout Ratio
64.42%
5 Year Growth Rate (CAGR)
15.01%
Years of Growth
9 Years
Latest Announced Dividend
$1.30
Ex-Dividend Date
5/15/2024
Payout Date
6/10/2024
Frequency
Quarterly

LLY Dividend Growth History

LLY Ownership

Type
Common Stock Held
% of Shares Outstanding
Market Value
Composition
Institutions
791.07M
87.86%
635.16B
Corporations (Private)
26,880
0.00%
21.58M
Individuals / Insiders
1.32M
0.15%
1.06B
State Owned Shares
857,777
0.10%
688.72M
Public and Other
107.12M
11.90%
86.01B
Total
900.41M
100.00%
722.94B

LLY Peers

Title
JNJMRKAZNRHHBY
Company name
Johnson & Johnson
Merck & Co., Inc.
AstraZeneca PLC
Roche Holding AG
Industry
PharmaceuticalsPharmaceuticalsPharmaceuticalsPharmaceuticals
Market Cap
363.99B
331.19B
243.69B
208.03B
Employees
131,900
71,000
89,900
103,605

Go Premium to see ratings on LLY peers.

Risk

24M Beta
0.52
Altman Z Score
7.53

Technicals

Title
10D SMA
50D SMA
200D SMA
Simple Moving Average
774.27
762.06
649.44
Last Price vs SMA
+3.73%
+5.40%
+23.67%

LLY Income Statement

Revenue (TTM)
35.93B
Revenue Per Share
39.92
Gross Profit (TTM)
28.80B
EBITDA (TTM)
13.37B
Net Income (TTM)
6.14B
EPS Diluted (TTM)
$6.79
Full Income Statement »

LLY Balance Sheet

Total Cash (MRQ)
2.65B
Total Cash Per Share
2.73
Total Debt (MRQ)
26.35B
Total Debt to Equity (MRQ)
204.28%
Current Ratio (MRQ)
1.35
Quick Ratio (MRQ)
0.67
Full Balance Sheet »

LLY Cash Flow Statement

Cash from Operations (TTM)
3.68B
Cash from Investing (TTM)
-7.64B
Levered Free Cash Flow (TTM)
-1.23B
Unlevered Free Cash Flow (TTM)
-880.54M
Free Cash Flow / Share (TTM)
-$2.55

LLY Long Term Solvency

Total Debt / Equity (MRQ)
204.28
Total Debt / Capital (MRQ)
67.14
LT Debt / Equity (MRQ)
191.35
LT Debt / Total Capital (MRQ)
62.89
Total Liabilities / Total Assets (MRQ)
79.83

Discover More

You may be interested in:

Eli Lilly and Company (LLY) Frequently Asked Questions

  • 28 analysts have issued ratings. Wall Street analysts rate LLY as Bullish on average, for a Wall Street consensus of buy. View LLY’s ratings here. 13 Seeking Alpha authors also rated the stock, and their ratings often outperform those of Wall Street analysts. Here are their ratings on LLY
  • Eli Lilly and Company is currently listed on NYSE under LLY. One share of LLY stock can currently be purchased for approximately $802.91.
  • Eli Lilly and Company’s current P/E Non-GAAP (TTM) sector relative grade is F. With Seeking Alpha Premium, you can easily view each stock's full value grade, which takes into account key metrics such as P/E ratio, Price/Book, Price/Sales and Enterprise Value to EBITDA. See more detailed value information.
  • Yes, Eli Lilly and Company is publicly traded and listed as LLY on the NYSE. It is currently being traded for approximately $802.91. View more information on LLY here.
  • Eli Lilly and Company's stock symbol is LLY and currently trades under NYSE. It’s current price per share is approximately $802.91.
  • 28 Wall Street analysts have issued ratings. Currently, 21 analysts rated LLY as Bullish, 1 rated it Bearish, and 6 rated it Neutral. This suggests a possible increase. View LLY’s analyst predictions. 13 Seeking Alpha authors also rated the stock, and their ratings often outperform those of Wall Street analysts. Here are their ratings on LLY
  • The current EBIT margin for Eli Lilly and Company is 32.86%. See more in-depth value information here.
  • Eli Lilly and Company is expected to issue its next earnings report on 08/08/2024. In the previous quarter, Eli Lilly and Company reported $2.58 (diluted) earnings per share. And during the same period last year, Eli Lilly and Company earnings per share was $1.62 (diluted). View more of Eli Lilly and Company’s earnings history here.
  • Yes, LLY pays dividends. LLY’s latest announced quarterly dividend was declared on 05/06/2024 for $1.30 and goes ex-dividend on 05/15/2024. You can view LLY’s full dividend history and dividend summary on its Dividend Scorecard page.
  • People who follow Eli Lilly and Company (LLY) also follow NVO, MRK, UNH, ABT. Read more about LLY’s peers.
  • Over the past 5 years, Eli Lilly and Company’s stock price has increased by 588.94%. Eli Lilly and Company’s stock price is currently approximately $802.91. View more of Eli Lilly and Company’s past performance.

People Also Follow

Similar to LLY

SymbolLast PriceChange
JNJ
0
0.00%
Johnson & Johnson
MRK
0
0.00%
Merck & Co., Inc.
AZN
0
0.00%
AstraZeneca PLC
RHHBY
0
0.00%
Roche Holding AG
PFE
0
0.00%
Pfizer Inc.